spacer
home > ebr > Summer 2013
PUBLICATIONS

European Biopharmaceutical Review

ebr
Summer 2013

   
Text
PDF
bullet
STRATEGY AND FINANCE
New Finance Models

A Common Cause

Oliver Timmis at the AKU Society investigates how collaboration between medical research charities and patient organisations could fund vital studies.
 
view
download pdf
Science and Innovation
Phage Prevention

Detection Validation

The presence of bacteriophages in fermentation and the facility environment needs to be constantly monitored by microbiologists. But when this is not possible, what other options are there? Marcin Los at Phage Consultants sheds light on this growing problem.
 
view
download pdf
Rediscovery

More for Less

The advantages of drug repurposing are vast, however the development costs involved risk stifling this innovation, argues Bruce Bloom at Cures Within Reach.
 
view
download pdf
Regulation and Finance

Tailored Medicine

With the help of a revised European Directive, bespoke treatments are entering the oncology industry and are being presented as safer and more effective, as Vincent O’Neill and Debasish Roychowdhury at Sanofi Oncology demonstrate.
 
view
download pdf
Organism Development

All Systems Go

A new discipline has risen in recent years: systems biology. José Manuel Mas and Albert Pujol Torras at Anaxomics describe the two main strategies that are used in this scheme – the topological and the functional.
 
view
download pdf
bullet
BioResearch and Innovation
Genotoxicity Screening

Early Identification

Steve Beasley at Gentronix assesses the need for the early screening of genetic toxicity to minimise late-stage attrition costs and improve compound quality.
 
view
download pdf
BioDiscovery
Drug Development

Tunable Half-Life Technology

Mark Perkins at Novozymes Biopharma analyses the challenges of biological drugs’ short half-lives, and how extension technology could resolve this problem.
 
view
download pdf
bullet
Drug Discovery
Tailoring Treatments

Critical Overhaul

Rick Morrison at Comprehend Systems demonstrates how the combination of rising patient demands and pioneering new technology could be the solution to bespoke medicine.
 
view
download pdf
Repurposing

Intelligent Approaches

In order to develop the drug discovery market and find indications for orphan conditions, alternative methods have to be implemented.Robert Scoffin and Alan Rothaul at Re-Pharm investigate the potential of drug repurposing or reprofiling to address this issue.
 
view
download pdf
Anti-Infective Drugs

The PK/PD Complex

In revealing the specific distinctions of a compound, pharmacokinetic and pharmacodynamic properties are being used and are becoming an increasing area of interest, suggests medical author Deborah Erickson.
 
view
download pdf
Cancer Therapy

The T Cell Promise

The evolution of the cancer therapy field is progressing through the help of T cells, which may eventually prove able to eradicate tumours. Namir J Hassan and Joanne Oates at Immunocore discuss the potential of this strategy.
 
view
download pdf
bullet
BioRegional
Bioregional

Innovative India

Andrew Barrett at Cambridge Consultants illustrates how Indian pharmaceutical companies are planning to create super-generics, and how they could potentially become a major force in the connected health market.
 
view
download pdf
bullet
INTERVIEW
Industry Interview

Insider Information

Jon Weisberg of SAFE-BioPharma reveals his career motivation and looks forward to the future of the biopharma sector.
 
view
download pdf
bullet
RESEARCH AND DEVELOPMENT
Oncology Drugs

Purposeful Reprofiling

A burgeoning trend in cancer prevention has been the treatment of patients with drugs that have already been approved in therapeutic areas other than oncology, as Rachel Meighan-Mantha at Citeline explains.


 
view
download pdf
Vaccines

Prevention is Better than Cure

Emanuela Signori at CNR-IFT and Vito Michele Fazio at UCBM discuss how recent research into the immune system biology has led to new strategies within the DNA vaccination area.

 
view
download pdf
Gene Therapy

Great Promise

Introducing therapeutic genetic material into a disease cell to correct phentotypes is becoming a popular concept in curing monogenic conditions. Bobby Gaspar and Christine Rivat at UCL talk us through this model.
 
view
download pdf
Protein Drugs

The Sugar is the Key

Taegen Clary at Agilent explains how analytical methods can aid the manufacturing process of protein biologics, which are especially important at a time of increasing patent expirations.
 
view
download pdf
Detection Techniques

Identifying Impurities

Process-related contamination from host cells is a relentless problem that needs to be addressed. Andrew Kenyon at RSSL assesses the situation and suggests alternative methods to tackle this issue.
 
view
download pdf
   
spacer
Edited by
Dr Deborah O'Neil,
Chief Executive and Scientific Officer,
NovaBiotics Ltd
Published quarterly in
January, April,
July and October

News and Press Releases

Pharmapack Europe 2018 to Spotlight New Innovations and the Young Innovators who are Shaping the Industry


More info >>

White Papers

Future-proofing serialization solutions: the importance of strong level 3 capabilities

Adents

The complexities surrounding product serialization for pharmaceutical and medical device companies are immense. While current serialization requirements are limited to marking the unit of sale with a unique data carrier, by 2023 the process will require a product to be traceable through the entirety of its journey - from the individual package through the carton/pallet to its final point of distribution. In the United States, the Healthcare Distribution Management Association (HDMA) is suggesting that pharmaceutical companies begin to support this level of serialization, called aggregation, now. Around the world – in Europe and Asia in particular – disparate track and trace practices are incrementally moving toward a global standard that will, undoubtedly, be more stringent than today’s differing benchmarks. How can companies manage this transformation with the greatest degree of success while also minimizing business disruption? The key to creating an optimal implementation strategy is to select a serialization solution that has strong capabilities at all levels of technology. It’s also important to choose a solution that enables multi-phase implementation
More info >>

Industry Events

Pharmapack Europe 2018

7-8 February 2018, Hall 7.1, Paris Expo, Porte de Versailles, Paris.

As Europe's dedicated Pharmaceutical Packaging and Drug Delivery event, Pharmapack is the industry's go-to place to kick-off the year.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement